Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37° C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier.

Abstract: The subject invention provides a solid unit dosage form comprising pridopidine or pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the dosage form has a volume and wherein the ratio of the amount of pridopidine to the volume of the dosage form is 135-600 mg/ml.

Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a SGLT-2 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

Abstract: A system for producing pharmaceutical objects, such as tablets, granules and capsules, via 3D printing. The system comprises a 3D printing machine (2) with a mechanical system (3) movable in one or more directions, at least one print head (5) with a nozzle (37) being movable by the mechanical system and a base system (4) carrying a print base (6) for receiving a prepared mixture (27) applied by the print head (5). The system comprises at least one carrier (35) for holding a cartridge (28). Printing is done at formatted print locations (49) on the base (6). A method for producing pharmaceutical objects by providing at least one pharmaceutical substance in at least one cartridge, placing the cartridge in a carrier, establishing a fluid connection between a cartridge and a print head, moving the print head nozzle according to a program and dispensing the pharmaceutical substance to a print base.

Abstract: Various embodiments of a system for automated pellet pressing and vialing are disclosed herein.

Abstract: The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.

Abstract: The present invention provides a hard capsule comprising an outer and one inner capsule, wherein the outer capsule comprises a hydrophobic liquid and the inner capsule which comprises a composition comprising uncoated microorganisms and optionally at least one desiccant. The composition may comprise a filtrate composed of viable fecal bacteria useful forfecal microbiota transplantation (FMT) or a mixture of one or more different types of microorganisms isolated from intestinal microbiome, such as bacteria, archaea, virus, or fungi such as yeast. The composition may comprise a desiccant, preferably a food approved component which is degradable in the gastrointestinal tract. The hydrophobic liquid, if present, is preferably at least one edible oil. Also provided are methods of treating or preventing a dysbiosis in a human subject, comprising administering to the human subject at least one capsule of the invention.

Abstract: Compositions comprising a therapeutic agent encapsulated by an edible plant-derived microvesicle are provided. Methods of treating an inflammatory disorder and methods of treating a cancer are further provided and include administering an effective amount of a composition comprising a therapeutic agent encapsulated by an edible plant-derived microvesicle to a subject. Further provided are methods of diagnosing a colon cancer that include the steps of administering an edible plant-derived microvesicle incorporating a detectable label to a subject and then determining an amount of the detectable label in an intestine of the subject.

Abstract: A liquid composition which comprises an organic liquid diluent and a hydroxyalkyl methylcellulose which has a certain distribution of substituted hydroxyalkoxyl groups and unsubstituted hydroxyalkoxyl groups is stable over an extended time period. In the hydroxyalkyl methylcellulose hydroxyalkoxyl groups are classified into a fraction (A) and a fraction (B), wherein fraction (A) represents the sum of all molar fractions of substituted hydroxyalkoxyl groups having hydroxyl groups substituted further with methoxyl groups and fraction (B) represents the sum of all molar fractions of unsubstituted hydroxyalkoxyl groups having hydroxyl groups not substituted further with methoxyl groups and wherein the ratio fraction (A)/fraction (B) is at least 0.30. The liquid composition is useful for preparing a solid dispersion comprising at least one active ingredient in at least one hydroxypropyl methylcellulose by spray-drying.

Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.

Abstract: The present disclosure relates to a gel formulation for treating diabetic foot ulcer infections. The gel formulation comprises antibiotic loaded aquasomes, a gelling agent, a preservative, and a fluid medium. The gel formulation of the present disclosure can be used for treating diabetic foot ulcer infections in mammals.

Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with a taxane, such as, paclilaxei and its derivatives, which are water insoluble or poorly water soluble. The aggregates are formed by interaction of a taxane and a homopolymer. Such aggregates improve drug solubility, stability, delivery and efficacy.

Abstract: Pharmaceutical and nutraceutical compositions suitable for transdermal administration of plant-derived medicinal compounds are disclosed. The compositions comprise ground plant material (plant flour) and a dermally acceptable adhesive. In preferred embodiments, the plant flour is derived from Cannabis sp. and the adhesive is a polymer selected from the group consisting of acrylic polymers, silicone polymers, urethanes, isobutylenes, polyisobutylenes, vinyl acetate, and styrene polymers or copolymers.

Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.

Abstract: The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.

Abstract: Described herein are methods of using inhaled nitric oxide for treating pulmonary hypertension and/or improving oxygen saturation in a patient with a ventilation-perfusion (V/Q) mismatch and/or pulmonary hypertension associated with lung disease.

Abstract: The invention relates to the use of effective amount of Pelargonium graveolens essential oil or extract or constituents thereof selected from a group consisting of: (S)(?)citronellol, linalool, menthone and isomenthone or any combination thereof, in the preparation of a medicament for treating a mammal suffering from or susceptible to a neurodegenerative condition which can be improved or prevented by inhibition of acetylcholinesterase (ACliE).

Abstract: Various aspects of this patent document relate to methods to administer compositions comprising anionic cannabinoid molecules.

Abstract: The present invention belongs to the field of medicine, and relates to use of cannabidiol (CBD) in the treatment of pulmonary arterial hypertension. The CBD can be used as the only active ingredient or combined with other active ingredients to prepare a medicament for treating pulmonary arterial hypertension. Specifically, the present invention relates to use of any one selected from (1) to (3) in the preparation of a medicament for treating and/or preventing pulmonary arterial hypertension: (1) CBD, (2) a plant extract containing the CBD; and preferably, the plant extract is a cannabis extract, and (3) a pharmaceutical composition containing the CBD and one or more pharmaceutically acceptable adjuvants. In the present invention, upon experimental researches, it has found that the CBD has the function of inhibiting pulmonary arterial hypertension, and is especially suitable for treating the pulmonary arterial hypertension caused by hypoxemia.

Abstract: A composition comprising surfactant-enhanced phospholipid vesicles with one or more cannabinoid substance encapsulated therein is disclosed, wherein one or more surfactant is utilized for enhancing loading and increasing encapsulation efficiency of cannabinoid passenger molecules within phospholipid structures. A method is disclosed for making a surfactant-enhanced phospholipid vesicles with one or more cannabinoid substance encapsulated therein, wherein one or more surfactant is used for enhancing loading and increasing encapsulation efficiency of passenger molecules in phospholipid structures. A method of using surfactant-enhanced phospholipid vesicles with one or more cannabinoid substance encapsulated therein is disclosed wherein one or more surfactant enhances loading and increases encapsulation efficiency of cannabinoid substances in phospholipid structures.

Abstract: The present technology relates to methods of treating one or more behavioral symptoms (for example, anxiety) of 22q11.2 deletion syndrome in a subject by administering, e.g., transdermally, an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of 22q11.

Abstract: This invention discloses various cosmetics and topical formulations comprising cannabigerol, a non-psychoactive cannabinoid. The formulation may be an anti-aging cream for day or night application, a hand and nail cream, an eye cream, an acne treatment cream or tonic, an anti-diaper rash cream, a shampoo, a conditioner, a body wash, a face wash, deodorant spray, or a lip balm formulation. These topical and cosmetic formulations have speedy wound healing, skin firming, anti-bacterial, anti-dandruff, skin soothing, and UV ray protection properties.

Abstract: A composition, comprising: a. a retinoid; b. a polyphenol; and c. a zinc salt, calcium salt, selenium salt, bismuth salt, or a combination thereof.

Abstract: Described herein are compositions for delaying onset or delaying progression of frailty, reversing aging phenotype, extending healthspan, compressing morbidity, increasing lifespan and reducing formation of senescent cells.

Abstract: The present invention relates to a pharmaceutical composition for use in the treatment of pre-cancerous conditions of the cervix/anogenital region, non-melanoma skin cancers (NMSCs), or actinic keratosis wherein said composition comprises a surfactant, preferably an anionic or amphoteric surfactant.

Abstract: Disclosed are a composition and a perfume composition for inhibiting growth of breast cancer stem cells containing phenylacetaldehyde or a pharmaceutically acceptable salt thereof as an active (effective) ingredient, and a pharmaceutical composition, a food composition or the like for inhibiting metastasis of breast cancer, or treating or preventing breast cancer, including the composition. The phenylacetaldehyde inhibits growth of breast cancer cells and formation of breast cancer stem cells. In addition, the phenylacetaldehyde inhibits expression of self-renewal genes such as Nanog, Sox2, Oct4, and CD44 known to be specifically expressed in breast cancer stem cells, inhibits production of IL-6 known to be involved in formation of mammospheres of breast cancer stem cells, and inhibits STATS signaling pathways. Accordingly, the compound inhibits growth of breast cancer stem cells and is useful for the treatment of breast cancer.

Abstract: A nutraceutical composition comprising fullerene (e.g., C60), curcumin, and at least one of black seed oil and moringa oil. Preferably, the nutraceutical composition is substantially free of particles having a size greater than 0.2 ?m. The nutraceutical composition can be used to prevent and to treat eye conditions (e.g., cataract) by local administration to the eye, oral administration, or both.

Abstract: An anti-inflammatory and anti-oxidative nutraceutical composition containing C60 fullerene, a COX-2 inhibitor, and a medium chain triglyceride. The combined use of C60 and COX-2 inhibitor has unexpected benefits in promoting health, including synergistic effects in fighting cancer, slowing aging, and in some cases, reversing aging. Advantageously, Nigella sativa (“black seed”) oil is used to provide both medium chain triglycerides and COX-2 inhibitors.

Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.

Abstract: The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.

Abstract: Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse.

Abstract: Disclosed herein are methods for treating subjects having ADHD identifiable by levels of 3-IS in blood.

Abstract: Described herein are methods for the treatment of an ophthalmic disease or disorder comprising the administration of non-retinoid visual cycle modulators.

Abstract: The present invention relates to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide having the following chemical structure or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient, particularly to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide hydrochloride, to pharmaceutical dosage forms, to their preparation, their use and methods for therapeutic treatment.

Abstract: Polymeric particles and scaffolds containing anesthetic agents, their use for sustained local delivery of anesthetic agents, reduction of pain killer addiction and addiction risk, and methods of fabricating and administering polymeric particles containing anesthetic agents are described herein.

Abstract: An anti-oxidative, energy-boosting, and anti-aging nutraceutical composition containing fullerene substituted with functional groups, a medium chain triglyceride (preferably black seed oil), and the composition optionally includes one or more energy molecules not bound to the fullerene. Preferred functional groups and energy molecules include beta-hydroxybutyrate (more preferably D-beta-hydroxybutyrate) and carboxylic acids (e.g., caprylic acid and/or capric acid).

Abstract: Disclosed herein are methods for treating hair related disorders, including compounds that may be specific or modulate PPAR receptors.

Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.

Abstract: Disclosed are a sustained release suspension containing dezocine analogue ester and a preparation method therefor. According to the present invention, an injectable oily auxiliary material which may pharmaceutically serve as a sustained-release depot and an excipient are selected, and micronization technology is used jointly with high pressure homogenization technology and an anti-solvent technique to prepare an injectable long-acting suspension. The main components of the suspension are a compound represented by formula (I), the injectable oil, and the like.

Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.

Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.

Abstract: Embodiments of the present invention are directed to formulations and methods of treating iron deficiency anemia. The dosage form has an effective amount of an iron supplement with an effective amount of a gingerol composition to suppress nausea and/or gastric distress and to promote hematopoiesis.

Abstract: One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions. Fasted conditions may comprise administering the tasimelteon without food, no food at least ½ hour prior to administration, no food at least 1 hour prior to administration, no food at least 1½ hours prior to administration, no food at least 2 hours prior to administration, no food at least 2½ hours prior to administration, or no food at least 3 hours prior to administration. According to such embodiments, tasimelteon may be administered, for example, at a dose of 20 mg/d. Tasimelteon may be administered where, for example, the patient is being treated for a circadian rhythm disorder or for a sleep disorder, including, for example, Non-24 Disorder.

Abstract: A method of oral administration of cannabinoids includes the steps of administering at least one first softgel containing a non-psychoactive cannabinoid and no psychoactive cannabinoids for a first administration cycle to the subject, administering at least one second softgel containing a first cannabinoid mix having the non-psychoactive cannabinoid and a psychoactive cannabinoid for a second administration cycle to the subject, wherein the first cannabinoid mix has no more than 10% on a w:w basis of the psychoactive cannabinoid, administering at least one third softgel containing a second cannabinoid mix having the first non-psychoactive cannabinoid and the psychoactive cannabinoid for a third administration cycle to the subject, wherein the second cannabinoid mix has no more than 50% on a w:w basis of the psychoactive cannabinoid.

Abstract: The present invention discloses a pharmaceutical topical composition comprising cannabidiol (CBD) or a derivative thereof and Tetrahydrocannabinol (THC) or a derivative thereof in an about 1:1 ratio, useful for treatment or prevention of inflammatory skin disorders, and treatment methods thereof.

Abstract: Provided herein are embodiments related to metered dose inhalers and formulations for such inhalers. In some embodiments, the inhalers are configured so as to allow a more comfortable experience for the subject receiving the formulation. In some embodiments, the formulation comprises various ingredients, such as terpenes and/or waxes, which can further enhance the level of comfort for the subject receiving the formulation.

Abstract: The present invention discloses a composition comprising not less than 10% w/w of oroxylin A, not less than 10% w/w of baicalein and not less than 2% w/w of chrysin for use in the therapeutic management of epilepsy.

Abstract: A topical hair and skin formulation which has primarily medicinal and healing properties, but may also be used to moisturize skin and dress or style hair of all types. The formulation is a blend of oils each having various individual properties. The invented oil blend keeps connective tissues strong and supple while protecting against the breakdown of the skin's cell structure and the hair's follicle and inner cuticle with essential vitamins, minerals, amino and fatty acids implementing healing and regeneration. The invented oil blend stimulates blood circulation and has anti-inflammatory, anti-oxidant, anti-bacterial, antimicrobial, antiviral, antifungal, analgesic, and hypoallergenic properties. The method of making the formulation ensures proper emulsification, a long shelf life, as well as a proper balance of the various ingredients to enhance effectiveness.

Abstract: The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating a bone-related disease; and the pharmaceutical composition is very effective in preventing or treating bone-related diseases in that it not only promotes differentiation of preosteoblast cells into osteoblasts to induce production of mineralized nodules, but also, at the same time, inhibits differentiation of bone marrow cells into osteoclasts and the function of osteoclasts so that bone homeostasis is effectively regulated.